{"schema_version":"secwatch.filing_event.v1","accession":"0001804220-21-000031","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.925671+00:00","generated_at":"2026-06-28T13:32:15.635225+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Regeneron Q3 revenues $3.45B (+51% YoY); GAAP EPS $14.33, non-GAAP $15.37","bullets":["Total revenues $3.45B, up 51% YoY; GAAP net income $1.63B ($14.33 diluted EPS); non-GAAP net income $1.77B ($15.37 diluted EPS).","EYLEA U.S. net sales $1.47B (+12% YoY); Dupixent global net sales (Sanofi) $1.66B (+55% YoY).","REGEN-COV contributed $804M (U.S. product sales $677M + Roche profit share); new U.S. government supply agreement for 1.4M doses.","Pipeline: FDA expanded Dupixent to children 6-11 with asthma; positive Phase 3 data in CSU, EoE, prurigo nodularis; REGEN-COV BLA accepted for priority review.","FY 2021 guidance updated: R&D lowered to $2.845-2.915B GAAP; SG&A narrowed to $1.76-1.83B; gross margin ~87.5% GAAP; capex reduced."],"urls":{"canonical":"https://secwatch.observer/filing/0001804220-21-000031","json":"https://secwatch.observer/filing/0001804220-21-000031.json","markdown":"https://secwatch.observer/filing/0001804220-21-000031.md","text":"https://secwatch.observer/filing/0001804220-21-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000180422021000031/0001804220-21-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000180422021000031/regn-20211104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:32:15.635225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}